Mereo Biopharma Group Plc ADR (MREO) concluded trading on Wednesday at a closing price of $2.94, with 4.99 million shares of worth about $14.66 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.18% during that period and on July 09, 2025 the price saw a gain of about 3.89%. Currently the company’s common shares owned by public are about 159.00M shares, out of which, 132.68M shares are available for trading.
Stock saw a price change of 6.52% in past 5 days and over the past one month there was a price change of 7.30%. Year-to-date (YTD), MREO shares are showing a performance of -19.01% which decreased to -16.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.58 but also hit the highest price of $5.02 during that period. The average intraday trading volume for Mereo Biopharma Group Plc ADR shares is 1.37 million. The stock is currently trading 5.51% above its 20-day simple moving average (SMA20), while that difference is up 14.80% for SMA50 and it goes to -5.32% lower than SMA200.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) currently have 159.00M outstanding shares and institutions hold larger chunk of about 61.06% of that.
The stock has a current market capitalization of $467.46M and its 3Y-monthly beta is at 0.45. It has posted earnings per share of -$0.31 in the same period. It has Quick Ratio of 8.92 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MREO, volatility over the week remained 6.49% while standing at 5.78% over the month.
Stock’s fiscal year EPS is expected to rise by 58.86% while it is estimated to decrease by -68.78% in next year. EPS is likely to shrink at an annualized rate of 25.31% for next 5-years, compared to annual growth of 34.82% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on March 27, 2025 offering an Overweight rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Mereo Biopharma Group Plc ADR (MREO) stock as a Buy in their note to investors on December 06, 2024, suggesting a price target of $7 for the stock. On June 13, 2024, Robert W. Baird Initiated their recommendations, while on October 13, 2023, BTIG Research Resumed their ratings for the stock with a price target of $4. Stock get an Overweight rating from Cantor Fitzgerald on August 12, 2022.
